Gene · 7307
Papers3,382
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
701 to 720 of 3,382
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Treatment Outcomes and Prognostic Factors in 66 Patients with Chronic Myelomonocytic Leukemia (CMML) in a Single Center. | Int J Gen Med | 2022 | 36644378 | PubTator, text mining | PubMed |
| Novel targeted treatments in hairy cell leukemia and other hairy cell-like disorders. | Front Oncol | 2022 | 36620555 | PubTator, text mining | PubMed |
| The Impact of Mutation of Myelodysplasia-Related Genes in De Novo Acute Myeloid Leukemia Carrying NPM1 Mutation. | Cancers (Basel) | 2022 | 36612194 | PubTator, text mining | PubMed |
| Impact of Molecular Biology in Diagnosis, Prognosis, and Therapeutic Management of BCR::ABL1-Negative Myeloproliferative Neoplasm. | Cells | 2022 | 36611899 | PubTator, text mining | PubMed |
| Coagulation status and determinants of possible aspirin resistance in patients with essential thrombocythemia. | Front Med (Lausanne) | 2022 | 36606056 | PubTator, text mining | PubMed |
| Reversal of splicing infidelity is a pre-activation step in B cell differentiation. | Front Immunol | 2022 | 36601126 | PubTator, text mining | PubMed |
| Deconvolution of in vivo protein-RNA contacts using fractionated eCLIP-seq. | STAR Protoc | 2022 | 36595959 | PubTator, text mining | PubMed |
| Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement? | Ther Adv Med Oncol | 2022 | 36570410 | PubTator, text mining | PubMed |
| High efficacy of azacitidine combined with homoharringtonine, idarubicin, and cytarabine in newly diagnosed patients with AML: A single arm, phase 2 trial. | Front Oncol | 2022 | 36568250 | PubTator, text mining | PubMed |
| Case report: Chronic neutrophilic leukemia associated with monoclonal gammopathies. A case series and review of genetic characteristics and practical management. | Front Oncol | 2022 | 36568246 | PubTator, text mining | PubMed |
| Pre-transplant gene profiling characterization by next-generation DNA sequencing might predict relapse occurrence after hematopoietic stem cell transplantation in patients affected by AML. | Front Oncol | 2022 | 36568206 | PubTator, text mining | PubMed |
| The Role of the m6A RNA Methyltransferase METTL16 in Gene Expression and SAM Homeostasis. | Genes (Basel) | 2022 | 36553579 | PubTator, text mining | PubMed |
| Pathophysiological Role and Diagnostic Potential of R-Loops in Cancer and Beyond. | Genes (Basel) | 2022 | 36553448 | PubTator, text mining | PubMed |
| Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia. | Biomedicines | 2022 | 36551764 | PubTator, text mining | PubMed |
| Leukemic stem cells and advances in hematopoietic stem cell transplantation for acute myeloid leukemia: a narrative review of clinical trials. | Stem Cell Investig | 2022 | 36540355 | PubTator, text mining | PubMed |
| Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation. | Blood Cancer J | 2022 | 36529759 | PubTator, text mining | PubMed |
| Oncogenic KRAS alters splicing factor phosphorylation and alternative splicing in lung cancer. | BMC Cancer | 2022 | 36522653 | PubTator, text mining | PubMed |
| Heterogeneous nuclear ribonucleoprotein K is overexpressed in acute myeloid leukemia and causes myeloproliferation in mice via altered Runx1 splicing. | NAR Cancer | 2022 | 36518526 | PubTator, text mining | PubMed |
| Management of patients with lower-risk myelodysplastic syndromes. | Blood Cancer J | 2022 | 36517487 | PubTator, text mining | PubMed |
| Splicing factor deficits render hematopoietic stem and progenitor cells sensitive to STAT3 inhibition. | Cell Rep | 2022 | 36516770 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7307/papers?page=36